Literature DB >> 17107340

Postulated role of interdomain interaction between regions 1 and 2 within type 1 ryanodine receptor in the pathogenesis of porcine malignant hyperthermia.

Takashi Murayama1, Toshiharu Oba, Hiroshi Hara, Kikuo Wakebe, Noriaki Ikemoto, Yasuo Ogawa.   

Abstract

We have demonstrated recently that CICR (Ca2+-induced Ca2+ release) activity of RyR1 (ryanodine receptor 1) is held to a low level in mammalian skeletal muscle ('suppression' of the channel) and that this is largely caused by the interdomain interaction within RyR1 [Murayama, Oba, Kobayashi, Ikemoto and Ogawa (2005) Am. J. Physiol. Cell Physiol. 288, C1222-C1230]. To test the hypothesis that aberration of this suppression mechanism is involved in the development of channel dysfunctions in MH (malignant hyperthermia), we investigated properties of the RyR1 channels from normal and MHS (MH-susceptible) pig skeletal muscles with an Arg615-->Cys mutation using [3H]ryanodine binding, single-channel recordings and SR (sarcoplasmic reticulum) Ca2+ release. The RyR1 channels from MHS muscle (RyR1MHS) showed enhanced CICR activity compared with those from the normal muscle (RyR1N), although there was little or no difference in the sensitivity to several ligands tested (Ca2+, Mg2+ and adenine nucleotide), nor in the FKBP12 (FK506-binding protein 12) regulation. DP4, a domain peptide matching the Leu2442-Pro2477 region of RyR1 which was reported to activate the Ca2+ channel by weakening the interdomain interaction, activated the RyR1N channel in a concentration-dependent manner, and the highest activity of the affected channel reached a level comparable with that of the RyR1MHS channel with no added peptide. The addition of DP4 to the RyR1MHS channel produced virtually no further effect on the channel activity. These results suggest that stimulation of the RyR1MHS channel caused by affected inter-domain interaction between regions 1 and 2 is an underlying mechanism for dysfunction of Ca2+ homoeostasis seen in the MH phenotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17107340      PMCID: PMC1798429          DOI: 10.1042/BJ20061040

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  48 in total

1.  Postulated role of interdomain interaction within the ryanodine receptor in Ca(2+) channel regulation.

Authors:  T Yamamoto; R El-Hayek; N Ikemoto
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

2.  Peptide probe study of the critical regulatory domain of the cardiac ryanodine receptor.

Authors:  Takeshi Yamamoto; Noriaki Ikemoto
Journal:  Biochem Biophys Res Commun       Date:  2002-03-08       Impact factor: 3.575

Review 3.  Altered ryanodine receptor function in central core disease: leaky or uncoupled Ca(2+) release channels?

Authors:  Robert T Dirksen; Guillermo Avila
Journal:  Trends Cardiovasc Med       Date:  2002-07       Impact factor: 6.677

Review 4.  Genetics and pathogenesis of malignant hyperthermia.

Authors:  K Jurkat-Rott; T McCarthy; F Lehmann-Horn
Journal:  Muscle Nerve       Date:  2000-01       Impact factor: 3.217

Review 5.  Ryanodine receptor/Ca2+ release channels and their regulation by endogenous effectors.

Authors:  G Meissner
Journal:  Annu Rev Physiol       Date:  1994       Impact factor: 19.318

6.  Redox states of type 1 ryanodine receptor alter Ca(2+) release channel response to modulators.

Authors:  Toshiharu Oba; Takashi Murayama; Yasuo Ogawa
Journal:  Am J Physiol Cell Physiol       Date:  2002-04       Impact factor: 4.249

Review 7.  Ryanodine receptor mutations in malignant hyperthermia and central core disease.

Authors:  T V McCarthy; K A Quane; P J Lynch
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

Review 8.  Ryanodine receptor isoforms of non-Mammalian skeletal muscle.

Authors:  Yasuo Ogawa; Takashi Murayama; Nagomi Kurebayashi
Journal:  Front Biosci       Date:  2002-05-01

Review 9.  Regulation of calcium release by interdomain interaction within ryanodine receptors.

Authors:  Noriaki Ikemoto; Takeshi Yamamoto
Journal:  Front Biosci       Date:  2002-03-01

10.  Caffeine stimulation of malignant hyperthermia-susceptible sarcoplasmic reticulum Ca2+ release channel.

Authors:  N H Shomer; J R Mickelson; C F Louis
Journal:  Am J Physiol       Date:  1994-11
View more
  10 in total

1.  Localization of an NH(2)-terminal disease-causing mutation hot spot to the "clamp" region in the three-dimensional structure of the cardiac ryanodine receptor.

Authors:  Ruiwu Wang; Wenqian Chen; Shitian Cai; Jing Zhang; Jeff Bolstad; Terence Wagenknecht; Zheng Liu; S R Wayne Chen
Journal:  J Biol Chem       Date:  2007-04-23       Impact factor: 5.157

2.  Role of amino-terminal half of the S4-S5 linker in type 1 ryanodine receptor (RyR1) channel gating.

Authors:  Takashi Murayama; Nagomi Kurebayashi; Toshiharu Oba; Hideto Oyamada; Katsuji Oguchi; Takashi Sakurai; Yasuo Ogawa
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

3.  Effects of conformational peptide probe DP4 on bidirectional signaling between DHPR and RyR1 calcium channels in voltage-clamped skeletal muscle fibers.

Authors:  Rotimi O Olojo; Erick O Hernández-Ochoa; Noriaki Ikemoto; Martin F Schneider
Journal:  Biophys J       Date:  2011-05-18       Impact factor: 4.033

4.  Gene dose influences cellular and calcium channel dysregulation in heterozygous and homozygous T4826I-RYR1 malignant hyperthermia-susceptible muscle.

Authors:  Genaro C Barrientos; Wei Feng; Kim Truong; Klaus I Matthaei; Tianzhong Yang; Paul D Allen; José R Lopez; Isaac N Pessah
Journal:  J Biol Chem       Date:  2011-12-02       Impact factor: 5.157

5.  Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene.

Authors:  Gennady Cherednichenko; Chris W Ward; Wei Feng; Elaine Cabrales; Luke Michaelson; Montserrat Samso; José R López; Paul D Allen; Isaac N Pessah
Journal:  Mol Pharmacol       Date:  2008-01-02       Impact factor: 4.436

6.  Reduced threshold for luminal Ca2+ activation of RyR1 underlies a causal mechanism of porcine malignant hyperthermia.

Authors:  Dawei Jiang; Wenqian Chen; Jianmin Xiao; Ruiwu Wang; Huihui Kong; Peter P Jones; Lin Zhang; Bradley Fruen; S R Wayne Chen
Journal:  J Biol Chem       Date:  2008-05-27       Impact factor: 5.157

7.  Muscle weakness in Ryr1I4895T/WT knock-in mice as a result of reduced ryanodine receptor Ca2+ ion permeation and release from the sarcoplasmic reticulum.

Authors:  Ryan E Loy; Murat Orynbayev; Le Xu; Zoita Andronache; Simona Apostol; Elena Zvaritch; David H MacLennan; Gerhard Meissner; Werner Melzer; Robert T Dirksen
Journal:  J Gen Physiol       Date:  2010-12-13       Impact factor: 4.086

8.  Divergent Activity Profiles of Type 1 Ryanodine Receptor Channels Carrying Malignant Hyperthermia and Central Core Disease Mutations in the Amino-Terminal Region.

Authors:  Takashi Murayama; Nagomi Kurebayashi; Toshiko Yamazawa; Hideto Oyamada; Junji Suzuki; Kazunori Kanemaru; Katsuji Oguchi; Masamitsu Iino; Takashi Sakurai
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

9.  Functional analysis of RYR1 variants linked to malignant hyperthermia.

Authors:  Jeremy Stephens; Anja H Schiemann; Cornelia Roesl; Dorota Miller; Sean Massey; Neil Pollock; Terasa Bulger; Kathryn Stowell
Journal:  Temperature (Austin)       Date:  2016-02-26

Review 10.  Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.

Authors:  Tokunbor A Lawal; Emily S Wires; Nancy L Terry; James J Dowling; Joshua J Todd
Journal:  Orphanet J Rare Dis       Date:  2020-05-07       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.